Literature DB >> 5435189

Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas.

G A Currie.   

Abstract

Corynebacterium parvum used alone to enhance immunological reactivity produced transient inhibition of the growth of chemically induced isogenic mouse tumours. Attempts were made to combine C. Parvum with cyclophosphamide to see whether this would increase the latter's effectiveness in inhibiting early but established tumours. Of the various regimens tested, the administration of the C. parvum 12 days after a single dose of chemotherapy produced dramatic inhibition of tumour growth and resulted in complete and lasting regressions in up to 70% of tumour-bearing animals. The most important variable in this regimen is the time between the chemotherapy and the subsequent immunotherapy.It is possible that non-specific active immunotherapy with agents such as C. parvum may be a valuable adjunct to the conventional cyto-reductive treatments of cancer, but the time of administration of such therapy is probably critical for each tumour and for each chemotherapeutic regimen.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5435189      PMCID: PMC1699572          DOI: 10.1136/bmj.1.5695.541

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  SUPPRESSION OF TISSUE IMMUNITY BY CYCLOPHOSPHAMIDE.

Authors:  M FOX
Journal:  Transplantation       Date:  1964-07       Impact factor: 4.939

2.  COMBINATION THERAPY WITH CYCLOPHOSPHAMIDE AND ZYMOSAN ON A SPONTANEOUS MAMMARY CANCER IN MICE.

Authors:  D S MARTIN; P HAYWORTH; R A FUGMANN; R ENGLISH; H W MCNEILL
Journal:  Cancer Res       Date:  1964-05       Impact factor: 12.701

3.  AN IMMUNOLOGICAL METHOD OF INCREASING THE SENSITIVITY OF PRIMARY SARCOMAS TO LOCAL IRRADIATION WITH X RAYS.

Authors:  A HADDOW; P ALEXANDER
Journal:  Lancet       Date:  1964-02-29       Impact factor: 79.321

4.  [ADJUVANT PROPERTIES OF CORYNEBACTERIUM PARVUM ON ANTIBODY PRODUCTION AND ON THE INDUCTION OF DELAYED HYPERSENSITIVITY TOWARD CONJUGATED PROTEINS].

Authors:  T NEVEU; A BRANELLEC; G BIOZZI
Journal:  Ann Inst Pasteur (Paris)       Date:  1964-05

5.  Experimental studies on Mitomycin C. 4. Zymosan and the R. E. S.

Authors:  B SOKOLOFF; Y TODA; M FUJISAWA; K ENOMOTO; C C SAELHOF; L BIRD; C MILLER
Journal:  Growth       Date:  1961-09

6.  Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse.

Authors:  L J OLD; D A CLARKE; B BENACERRAF
Journal:  Nature       Date:  1959-07-25       Impact factor: 49.962

7.  An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice.

Authors:  J P Glynn; B L Halpern; A Fefer
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

8.  Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.

Authors:  E Mihich
Journal:  Cancer Res       Date:  1969-04       Impact factor: 12.701

9.  Choriocarcinoma after hydatidiform mole. Studies related to effectiveness of follow-up practice after hydatidiform mole.

Authors:  K D Bagshawe; P R Golding; A H Orr
Journal:  Br Med J       Date:  1969-09-27

10.  Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts.

Authors:  M F Woodruff; J L Boak
Journal:  Br J Cancer       Date:  1966-06       Impact factor: 7.640

View more
  25 in total

Review 1.  Salmonella-allies in the fight against cancer.

Authors:  Sara Leschner; Siegfried Weiss
Journal:  J Mol Med (Berl)       Date:  2010-06-05       Impact factor: 4.599

2.  Some 'in vitro' effects of bacterial filtrates on normal lymphocytes and leukaemic cells.

Authors:  J de Azavedo; J F Greally
Journal:  Ir J Med Sci       Date:  1975-12       Impact factor: 1.568

3.  Effects of "Bordetella pertussis" on hemic colony-forming cells and immune response.

Authors:  E M Uyeki; A ElAshkar; T L Pazdernik
Journal:  Agents Actions       Date:  1974-10

4.  Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.

Authors:  C Liu; B F Kimler; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

5.  Combined adjuvant therapy of radically operated colorectal cancer patients. (chemotherapy, radiotherapy, and MER-BCG).

Authors:  E Robinson; A Bartal; Y Cohen; N Haim; J Mohilever; T Mekori
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes.

Authors:  Debika Biswal Shinohara; Ajay M Vaghasia; Shu-Han Yu; Tim N Mak; Holger Brüggemann; William G Nelson; Angelo M De Marzo; Srinivasan Yegnasubramanian; Karen S Sfanos
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

7.  Adjuvant immune stimulation with Corynebacterium parvum during maintenance chemotherapy of acute myeloid leukemia. A prospective randomized study.

Authors:  E la Cour Petersen; P Hokland; J Ellegaard
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.

Authors:  Katsuki Ito; Hiroaki Nakazato; Akihiko Koike; Hiroshi Takagi; Shigetoyo Saji; Shozo Baba; Masayoshi Mai; Jun-ichi Sakamoto; Yasuo Ohashi
Journal:  Int J Colorectal Dis       Date:  2003-09-12       Impact factor: 2.571

9.  Effect of Corynebacterium acnes on interferon production in mice.

Authors:  P A Farber; L A Glasgow
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

10.  Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer.

Authors:  H D Adolphs; J Thiele; H Kiel
Journal:  Urol Res       Date:  1979-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.